Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Panel: Investing Beyond IO Set To Heat Up

Executive Summary

Panelists at the World Medical Innovation Forum discussed the new opportunities they are looking at and where the money will be going in the future.

You may also be interested in...

Viehbacher On Boston Pharmaceuticals: A New Model To De-Risk Drugs

Gurnet Point Capital, the $2bn health care and life science investment firm that recruited former Sanofi CEO Christopher Viehbacher earlier this year, has committed $600m to one of Viehbacher's pet projects: a company called Boston Pharmaceuticals that will bridge the valley of death between promising early-stage drugs and big pharma's aversion to research and development risk.

Video: Chris Viehbacher Interviewed At BioPharm America

Since his departure from Sanofi, Christopher Viehbacher has taken on a significant role in venture capital. At the BioPharm America 2015 conference in Boston, Massachusetts, he spoke about his company's business model and goals, as well as the trend of pharma execs moving into smaller companies.

Viehbacher surfaces at $2bn Bertarelli fund

Christopher Viehbacher, ex-CEO of Sanofi, has been appointed as the managing partner of Waypoint Capital's US-based fund, Gurnet Point Capital. Waypoint is the investment vehicle of the Bertarelli family, former owners of Serono, which was sold to Merck KGaA of Germany in 2007 in a deal worth around €10bn. Waypoint's chairman is Ernesto Bertarelli, the former CEO of Serono.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts